NICE recommends acalabrutinib for chronic lymphocytic leukaemia

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
News Item
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085795/
https://www.ncbi.nlm.nih.gov/pubmed/33948080
http://dx.doi.org/10.1007/s40274-021-7683-2
_version_ 1783686417687248896
collection PubMed
description
format Online
Article
Text
id pubmed-8085795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80857952021-04-30 NICE recommends acalabrutinib for chronic lymphocytic leukaemia PharmacoEcon Outcomes News News Item Springer International Publishing 2021-05-01 2021 /pmc/articles/PMC8085795/ /pubmed/33948080 http://dx.doi.org/10.1007/s40274-021-7683-2 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News Item
NICE recommends acalabrutinib for chronic lymphocytic leukaemia
title NICE recommends acalabrutinib for chronic lymphocytic leukaemia
title_full NICE recommends acalabrutinib for chronic lymphocytic leukaemia
title_fullStr NICE recommends acalabrutinib for chronic lymphocytic leukaemia
title_full_unstemmed NICE recommends acalabrutinib for chronic lymphocytic leukaemia
title_short NICE recommends acalabrutinib for chronic lymphocytic leukaemia
title_sort nice recommends acalabrutinib for chronic lymphocytic leukaemia
topic News Item
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085795/
https://www.ncbi.nlm.nih.gov/pubmed/33948080
http://dx.doi.org/10.1007/s40274-021-7683-2

Ejemplares similares